Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive ma...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yoshimoto, Takayuki, Mizoguchi, Izuru, Katagiri, Seiichiro, Tauchi, Tetsuzo, Furusawa, Jun-ichi, Chiba, Yukino, Mizuguchi, Junichiro, Ohyashiki, Junko H, Ohyashiki, Kazuma
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2014
Matèries:
Author's View
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4091524/
https://ncbi.nlm.nih.gov/pubmed/25057448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.28861
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars